<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226755</url>
  </required_header>
  <id_info>
    <org_study_id>ZOLCAR19001</org_study_id>
    <nct_id>NCT04226755</nct_id>
  </id_info>
  <brief_title>Liberal Use of Sodium in Ambulatory Heart Failure</brief_title>
  <acronym>LUSA-HF</acronym>
  <official_title>Liberal Use of Sodium in Ambulatory Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziekenhuis Oost-Limburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effects of an increased sodium intake in heart failure patients
      with reduced ejection fraction and age-matched volunteers without heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the start of the study, baseline investigations are performed including assessment of
      vital signs (blood pressure, heart rate, pulse oxygen saturation), weight, Everest congestion
      score (consisting of grading of dyspnea, orthopnea, jugular venous distention, rales, edema
      and fatigue), echocardiography, 24h urine collection, bio-impedance measurements and blood
      sample analysis with plasma renin and aldosterone Subsequently, a run-in phase of 2 weeks,
      without intervention, will start. After this run-in period, participants will be reassessed
      with the same baseline investigations. In addition, a skin biopsy will be performed as well
      as a blood volume measurement.

      In the next phase of the study, salt intake will be increased with 3 grams daily. The salt
      will be packed in capsules containing 1 g of sodium chloride (NaCl). Patients will be asked
      to take one capsule with their breakfast, lunch and dinner. Every 2 weeks a follow-up visit
      is planned.

      After 4 weeks of increased salt intake, a new skin biopsy will be taken and a blood volume
      measurement will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in skin glycosaminoglycan (GAG) content</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in skin sodium content</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood volume assessed by radiolabeled red blood cell technique</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in extracellular, intravascular volume and total body fluid volume (assessed with bioimpedance)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal sodium handling</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiac geometry assessed by echo</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal venous flow pattern</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Everest congestion score</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Everest score assesses congestion, based on a point scale with a range from 0 (no congestion) to 18 (worst congestion)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in weight</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in thirst visual analogue scale (VAS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The scale ranges from 0 -100 with 0 indicating no thirst and 100 the worst thirst.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in aldosterone</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in renin</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in N-terminal (NT)-pro hormone BNP (NT-proBNP)</measure>
    <time_frame>6 weeks</time_frame>
    <description>NT-proBNP will be measured using Roche diagnostics assay (Mannhein, Germany) and expresed as picogram per liter</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of congestion</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>1 gram tid (with every meal)</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_label>Heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Heart failure patients:

               -  Left ventricular ejection fraction â‰¤40% on echocardiogram obtained at inclusion

               -  Stable dose of guideline-recommended disease modifying drugs for at least 3
                  months.

               -  Maximum daily loop diuretic dose of 40 mg furosemide equivalents with a stable
                  dose for the last month

          2. Healthy volunteers:

               -  Age &gt; 60 y

               -  Normal ejection fraction (&gt;50%) without heart failure

               -  No neurohormonal blockers for hypertension

               -  Normal NT-proBNP

        Exclusion Criteria:

          -  Heart failure hospitalization for congestion or myocardial infarction in past 3 months

          -  Permanent atrial fibrillation

          -  New York Heart Association (NYHA) class III-IV

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min

          -  Signs of congestion

          -  Severe right ventricular dysfunction

          -  Severe valvular disease

          -  Cardiothoracic anatomy not allowing satisfactory and reproducible recordings of
             echocardiogram

          -  Inability to fully comprehend and/or perform study procedures in the investigator's
             opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen Dauw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Dauw, MD</last_name>
    <phone>+3289212062</phone>
    <email>jeroen.dauw@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wilfried Mullens, MD, PhD</last_name>
    <phone>+3289327110</phone>
    <email>wilfried.mullens@zol.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Mullens Wilfried, MD, PhD</last_name>
      <phone>+3289327110</phone>
      <email>wilfried.mullens@zol.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziekenhuis Oost-Limburg</investigator_affiliation>
    <investigator_full_name>Wilfried Mullens</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Sodium</keyword>
  <keyword>Salt</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

